Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG.
LoRusso PM, et al.
Invest New Drugs. 2017 Aug;35(4):442-450. doi: 10.1007/s10637-016-0413-0. Epub 2017 Feb 4.
Invest New Drugs. 2017.
PMID: 28161886
Free PMC article.
Clinical Trial.
Purpose Macrophage-stimulating 1-receptor (RON) is expressed on macrophages, epithelial cells, and a variety of tumors. Narnatumab (IMC-RON8; LY3012219) is a neutralizing monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP) …
Purpose Macrophage-stimulating 1-receptor (RON) is expressed on macrophages, epithelial cells, and a variety of tumors. Narnatumab (I …